Lionel Bouchet Promoted to Senior Vice President
Dr. Bouchet will lead North American Commercial Development for Mevion
Littleton, MA., JANUARY 21, 2022 - Mevion Medical Systems is pleased to announce the promotion of Lionel Bouchet, Ph.D., to Senior Vice President of Commercial Development, North America, effective January 18. A 15-year veteran of Mevion, Lionel’s knowledge, industry experience, and strong relationships with our colleagues, customers, and the radiation oncology community position him exceptionally well to lead Mevion's commercial team. We congratulate him and look forward to his continued leadership.
James Meng, Ph.D., President of Mevion, has decided to resign due to family priorities, effective January 31. James has been an integral member of our executive leadership team over the past four years. Mevion has benefitted greatly from his leadership during his tenure. While Mevion will miss his guidance, we recognize the importance of family, and thank him for his valuable contributions, and wish him the best as he moves forward. Tina Yu, PhD., CEO of Mevion, will absorb the role of President and will work closely with the commercial team to further advance Mevion’s success.
About Mevion Medical Systems
Since 2004, Mevion Medical Systems has been the leading provider of compact proton therapy systems for cancer care. Dedicated to advancing the design and accessibility of proton therapy worldwide, Mevion was the first company to innovate this new single-room platform and continues to further the science and application of proton therapy. Mevion’s flagship product, the MEVION S250i Proton Therapy System with HYPERSCAN pencil beam scanning, is the world’s smallest proton therapy system that eliminates the obstacles of size, complexity, and cost that exists with other proton therapy systems. Mevion is headquartered in Littleton, Massachusetts, with a presence in Europe and Asia. For more information, please visit www.mevion.com.